



## CONTACT US:

**Brian B. Berger, MD**  
[bberger@e-retina.net](mailto:bberger@e-retina.net)

**Chirag Jhaveri, MD**  
[cjhaveri@e-retina.net](mailto:cjhaveri@e-retina.net)

**Ginger Manhart**  
[gmanhart@e-retina.net](mailto:gmanhart@e-retina.net)  
 512-279-1250

- **XOMA**

**Ivana Gunderson**  
[igunderson@e-retina.net](mailto:igunderson@e-retina.net)  
 512-279-1251


- **GSK BAM114341**
- **Ampio Optina**
- **Lpath Nexus**
- **Alcon C-13-001**

## Dr Jhaveri and Dr. Berger are first in the country to enroll a patient in the Alcon ESBA1008 microrvolume infusion vs Lucentis trial


Retina Research Center is currently working with Alcon on a Phase 2 study evaluating the efficacy of a microvolume injection or infusion of ESBA1008 versus an intravitreal injection of Lucentis in treatment naïve patients with exudative ARMD. ESBA1008 is a humanized monoclonal antibody fragment that targets VEGF-A. Unlike the full length IgG (150 kDa) and Fab fragments (50kDa) which are marketed as Lucentis and Eylea respectively, ESBA1008 is a single chain molecule that is only 26 kDa in size. Its' small size and high affinity to VEGF could lead to longer treatment intervals compared to current FDA approved therapy. The Phase 2, C-13-001 trial is designed to enroll a total of 26 patients into two cohorts: Cohort 1 - intravitreal injection of ESBA1008 versus Lucentis and Cohort 2 - microvolume infusion of ESBA1008 versus Lucentis. Retina Research Center is proud to be the first site to screen and enroll a patient in the microrvolume infusion versus Lucentis Cohort. Enrollment is open to treatment naïve wet ARMD patients that would like to participate in a two month trial that could potentially bring a novel drug and drug delivery system to market.

Compensation is provided for time and transportation for all visits. Please call Retina Research Center if you have any interested patients or would like more information about this trial. **512-454-0138**

### Cohort 1



### Cohort 2



Day 0

Day 28

Screen

## Plaquenil Testing Guidelines

The American Academy of Ophthalmology (AAO) updated its Plaquenil guidelines in order to better detect early onset of Plaquenil toxicity. It is now recommended that routine Plaquenil testing include one of the following: spectral domain optical coherence tomography, mfERG or fundus autofluorescence. Early changes in the SD-OCT may reflect localized areas of macular thinning. Autofluorescence can detect early damage associated with localized areas of RPE defects characterized as a reduction of autofluorescence, while also indicating whether there is an increase in autofluorescence as indicative of photoreceptor damage.

As a reminder, we perform spectral domain optical coherence tomography as well as fundus autofluorescence per these new guidelines at both our Austin and Round Rock locations.

## Welcoming New Arrivals




We would like to congratulate Tori Moore and Jessica Solis on the new additions to their families. Jessica gave birth to her first child, Mila Jayne Aleman, on April 5. Jessica is the lead receptionist for Brian B Berger, MD, PA since January 2011.

Tori Moore gave birth to her first child, Jude Neal Moore on June 23. Tori is a research coordinator at Retina Research Center for one year. She is currently the coordinator for the DRCR network trials and performs visual acuity and refractions for all other trials.



## Best of Luck to our Future Doctor

Joseph Torres graduated from University of Texas Austin with a Bachelor of Science in December 2012. Mr. Torres worked alongside Dr. Jhaveri and Dr. Berger for seven months. Joseph has been accepted into medical school at University of Texas Health Science Center at San Antonio, starting his first year in Fall 2013. We are very proud of Joseph and wish him the best of luck on his path to becoming a physician.



## Special Thanks

**A special thank you goes to the following for referring patients in the past 6 months who consented to enroll in a clinical trial:**

Maureen Alexander, MD; Jim Kalpaxis, MD; Glen Underwood, OD; Mitchel Wong, MD; Erin Jacob, OD; Zarmeena Vendal, MD; Sundra Lemanski, OD; Shahrokh Rouhani, OD; Scott Snowberger, OD; Anne Miller, OD; Russell Swann, MD; Quynh Vu, OD; Doug Clark, OD; David Tybor, OD; Patricia Dearman, MD; Gary Gage, OD;



Dr. Berger,  
Dr.  
Jhaveri,  
and the  
Retina  
Research  
Center  
participate  
in training  
the future  
minds of  
medicine

## UT Southwestern Transitional Resident



William Pearce, MD spent the month of April training with Dr. Berger and Dr. Jhaveri during his transitional internship at University of Texas Southwestern Medical School. Dr. Pearce began his ophthalmology residency at Emory this July. He is the nephew of Steve Fisher, MD, of Medical Center Ophthalmology Associates in San Antonio. Dr. Pearce plans a career in retinal surgery.

## UT Southwestern Family Medicine Residents



Matthew Reynolds, MD spent July and August with our office as part of his surgical rotation for University of Texas Southwestern.

Marcee Vest, MD is a third year family medicine resident with the University of Texas Southwestern. Dr. Vest is spending the month of August training with our doctors. She plans to enter an obstetrics fellowship following residency.



## University of North Texas Health Science Center Medical Student

Emily Hsu, DO completed an ophthalmology elective in our office during the month of April 2013. She is an osteopathic medicine student from the University of North Texas Health Science Center Texas College of Osteopathic Medicine in Fort Worth. She began a family practice residency in July in Waco.



## Texas A&M Health Science Center College of Medicine Medical Student



Steven Glenn, B.S. graduated magna cum laude from Brigham Young University. He will graduate from Texas A&M Health Science Center College of Medicine in May 2014. He is interested in a career in general ophthalmology with the possibility of a fellowship. He spent the month of July with doctors Berger and Jhaveri.





## Enrolling Trials

### Wet Age-Related Macular Degeneration

- **LPATH NEXUS** - A Phase II study of iSONEP as either monotherapy or adjunctive therapy to Lucentis, Eylea or Avastin versus Lucentis, Eylea or Avastin alone for choroidal neovascularization secondary to ARMD that has not adequately responded to at least 3 Treatments within the prior 12 months.
- **ALCON C13001** - A study to evaluate the effect ESBA1008 applied by microvolume injection or infusion in subjects with treatment naïve exudative age-related macular degeneration

### Dry Age-Related Macular Degeneration

- **GSK BAM114341** - A phase II study of GSK933776, a monoclonal antibody, in patients with geographic atrophy (GA) secondary to age-related macular degeneration. Fellow eye CNV is permitted.

### Uveitis

- **XOMA X052130/ CL3-78989-005** - A Phase III study of monthly subcutaneous injections of gevokizumab in the treatment of active or steroid maintained stable non-infectious intermediate, posterior, or pan-uveitis.

### Diabetic Macular Edema

- **AMPIOAP05-002** - A Phase IIb study to evaluate two doses of oral Optina™ in adult patients with diabetic macular edema. The study drug is a low dose of Danazol™, which is marketed for the treatment of endometriosis and benign fibrocystic breast disease.

## Presentations & Publications

### BRIAN BERGER, MD

- Diabetic macular edema panel discussion: DRCR summer meeting, Chicago, IL August 2013
- Phase I, Masked, Placebo-Controlled, Single and Multiple Ascending Intravenous Dose Studies evaluating Systemic and Ocular Safety, Tolerability, and Visual Acuity effects of RN6G (PF- 04382923) in Subjects with Dry, Age-Related Macular Degeneration (ARMD), Retina Society, Beverly Hills, CA, September 26-29, 2013 (poster) and Association for Research in Vision and Ophthalmology Annual Meeting, Seattle, WA, May 2013 (presentation)
- Moderator, Infection and Inflammation, Retina Society, Beverly Hills, CA, September 26-29, 2013
- Faculty, Academy Café Retina, American Academy of Ophthalmology, New Orleans, LA, November 14-19, 2013
- Sclerotomy Closure for Retisert Implant”, Retina, February 2013, Volume 33, pages 436-438